Abstract
The inclusion complex formation of intravenously administered hydroxypropyl-β-cyclodextrin and β-cyclodextrin with endogenous lipids was studied. We tested the hypothesis that complex formation of endogenous cholesterol with cyclodextrins in the bloodstream leads to extraction of cholesterol from the large lipoprotein particles. The relatively small cholesterol–cyclodextrin complexes then leave the bloodstream via capillary pores, and dissociation of the complex in the extravascular compartment finally causes redistribution of cholesterol from blood to tissue. This hypothesis is supported by the following experimental findings. Intravenous administration of cyclodextrins led to a transient decrease in plasma cholesterol levels in a dose-dependent manner, and in vitro cholesterol-cyclodextrin complexes passed dialysis membranes with a molecular weight cutoff of 6000–8000. Further, cyclodextrins increased protein binding of the steroidal drug spironolactone, probably through removal of cholesterol from plasma protein binding sites. Finally, extravascular redistribution was directly demonstrated in histological studies of the kidneys. Glomerular filtration of the cholesterol–cyclodextrin complex is followed by dissociation of the complex in the ultrafiltrate, resulting in cholesterol accumulation in the proximal tubule cells. The cholesterol-β-cyclodextrin complex has a limited aqueous solubility. Crystallization of this complex in renal tissue might explain the nephrotoxicity of parenterally administered β-cyclodextrin. The absence of such crystallization might explain the lower nephrotoxicity of hydroxypropyl-β-cyclodextrin after intravenous administration.
Similar content being viewed by others
REFERENCES
H. W. Frijlink, J. Visser, N. R. Hefting, R. Oosting, D. K. F. Meijer, and C. F. Lerk. The pharmacokinetics of β-cyclodextrin and hydroxypropyl-β-cyclodextrin in the rat. Pharm. Res. 7:1248–1252 (1990).
J. Szejtli. Cyclodextrins and Their Inclusion Complexes, Akademiai Kiado, Budapest, 1982.
K. Uekama and M. Otagiri. Cyclodextrins in drug carrier systems. CRC Crit. Rev. Ther. Drug Carrier Syst. 3:1–40 (1986).
T. O. Carpenter, J. M. Pettifor, R. M. Russel, J. Pitha, S. Mohbaran, M. S. Ossip, S. Wainer, and C. S. Anast. Severe hypervitaminosis A in siblings: Evidence of variable tolerance to retinol intake. J. Pediat. 111:507–512 (1987).
J. Pitha and L. Szente. Rescue from hypervitaminosis A or potentiation of retinoid toxicity by different modes of cyclodextrin administration. Life Sci. 32:719–723 (1983).
D. W. Frank, J. E. Gray, and R. N. Weaver. Cyclodextrin nephrosis in the rat. Am. J. Pathol. 83:367–383 (1976).
J. Szejtli. The metabolism, toxicity and biological effects of cyclodextrins. In D. Duchêne (ed.), Cyclodextrins and Their Industrial Uses, Editions de Santé, Paris, 1987, pp. 175–210.
J. Serfozo, P. Szabo, Ferenczy, A. Toth-Jakab. Renal effects of parenterally administered methylated cyclodextrins on rabbits. In J. Szejtliu (ed.), I. Int. Symp. Cyclodextrins Budapest, 1981, D. Reidel, Dordrecht, 1982, pp. 123–132.
J. Szejtli and J. Pagington. Hydroxypropyl-βCD the new parenteral drug carrier. Cyclodextrin News 2 (8):1–5 (1988).
J. Pitha. Amorphous water soluble derivatives of cyclodextrins: from test tube to patient. J. Control. Rel. 6:309–313 (1987).
J. Pitha, L. Szente, and J. Szejtli. Molecular encapsulation of drugs by cyclodextrins and congeners. In S. D. Bruck (ed.), Controlled Drug Delivery, CRC Press, Boca Raton, FL, 1983, Vol. 1, pp 125–148.
T. Higuchi and K. Connors. Phase solubility techniques. Adv. Anal. Chem. Instr. 4:117–212 (1965).
L. A. Selvidge and M. R. Eftink. Spectral displacement techniques for studying the binding of spectroscopically transparent ligands to cyclodextrins. Anal. Biochem. 154:400–408 (1986).
H. W. Frijlink, A. J. M. Schoonen, and C. F. Lerk. The effects of cyclodextrins on drug absorption. I. In vitro observations. Int. J. Pharm. 49:91–102 (1989).
B. P. Lisboa. Chromatography of sterols and steroids. In G. V. Marinetti (ed.), Lipid Chromatographic Analysis, Marcel Dekker, New York, 1969, Vol. 2, pp. 57–148.
H. P. R. Bootsma, H. W. Frijlink, A. Eissens, J. H. Proost, H. Van Doorne, and C. F. Lerk. β-Cyclodextrin as an excipient in solid oral dosage forms: In vitro and in vivo evaluation of spraydried diazepam-β-cyclodextrin products. Int. J. Pharm. 51:213–223 (1989).
M. Vikmon. Rapid and simple spectrophotometric method for determination of micro-amounts of cyclodextrins. In J. Szejtli (ed.), I. Int. Symp. Cyclodextrins Budapest, 1981, D. Reidel, Dordrecht, 1982, pp. 69–74.
I. W. Duncan, P. H., Culbreth and C. A. Burtis. Determination of free, total, and esterfied cholesterol by high-performance liquid chromatography. J. Chromatogr. 162:281–292 (1979).
H. W. Frijlink, J. Visser, and B. F. H. Drenth. Determination of cyclodextrins in biological fluids by high-performance liquid chromatography with negative colorimetric detection using post-column complexation with phenolphthalein. J. Chromatogr. 415:325–333 (1987).
A. B. Steffens. A method for frequent sampling of blood and continuous infusion of fluids in the rat without disturbing the animal. Physiol. Behav. 4:833–836 (1969).
A. G. Everson Pearse. Histochemistry, Theoretical and Applied, J. & A. Churchill, London, 1960.
M. E. Haberland and J. A. Reynolds. Self-association of cholesterol in aqueous solution. Proc. Natl. Acad. Sci. USA 70:2313–2316 (1973).
R. J. Bergeron. Cycloamylose-substrate binding. In J. L. Atwood, J. E. D. Davies, and D. D. MacNicol (eds.), Inclusion Compounds, Academic Press, London, 1984, Vol. 3, pp. 391–443.
A. S. Ng, R. B. Kluza, and D. W. Newton. Distribution coefficients and in vitro human serum protein binding of spironolactone and its 7α-carboxymethyl analog. J. Pharm. Sci. 69:30–32 (1980).
Y. W. Chien, L. M. Hofmann, H. J. Lambert and L. C. Tao. Binding of spironolactones to human plasma proteins. J. Pharm. Sci. 65:1337–1340 (1976).
F. Mollgaard Andersen and H. Bundgaard. Inclusion complexation of spironolactone with cyclodextrins. Arch. Pharm. Chem. Sci. Ed. 11:7–14 (1983).
S. H. Quafordt and H. L. Hilderman. Quantitation of the in vitro free cholesterol exchange of human red cells and lipoproteins. J. Lipid Res. 11:528–535 (1970).
T. Irie, M. Otagiri, M. Sunada, K. Uekama, Y. Ohtani, Y. Yamada, and Y. Sugiyama. Cyclodextrin-induced hemolysis and shape changes of human erythrocytes in vitro. J. Pharm. Dyn. 5:741–744 (1982).
M. N. Cayen, L. Givner, and M. Kraml. Effect of diurnal rhythm and food withdrawal on serum lipid levels in the rat. Experientia 28:502–503 (1972).
P. Marino, D. Gavish, E. Shafrir, and S. Eisenberg. Diurnal variations of plasma lipids, tissue and plasma lipoprotein lipase, and VLDL secretion rates in the rat. A model for studies of VLDL metabolism. Biochim. Biophys. Acta 920:277–284 (1987).
K. R. Norum, T. Berg, P. Helgerud, and C. A. Drevon. Transport of cholesterol. Physiol Rev. 63:1343–1419 (1983).
D. Reichl and N. E. Miller. The anatomy and physiology of reverse cholesterol transport. Clin. Sci. 70:221–231 (1986).
K. Petrak and P. Goddard. Transport of macromolecules across the capillary walls. Adv. Drug Deliv. Rev. 3:191–214 (1989).
E. Vasile, A. Nistor, S. Nedelcu, M. Simionescu, and N. Simionescu. Dual pathway of low density lipoprotein transport through aortin endothelium, and vasa vasorum, in situ. Eur. J. Cell Biol. 22:181 (1980).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Frijlink, H.W., Eissens, A.C., Hefting, N.R. et al. The Effect of Parenterally Administered Cyclodextrins on Cholesterol Levels in the Rat. Pharm Res 8, 9–16 (1991). https://doi.org/10.1023/A:1015861719134
Issue Date:
DOI: https://doi.org/10.1023/A:1015861719134